In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
暂无分享,去创建一个
R. Tibshirani | R. Levy | R. Advani | D. Czerwinski | R. Hoppe | J. Brody | I. Wapnir | S. Knox | Youn H. Kim | W. Ai | L. Shin | J. Torchia | M. Levy | R. Levy
[1] S. Meijer,et al. Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients , 2008, Clinical Cancer Research.
[2] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Vose,et al. Results of a Phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymphoma (fNHL) , 2008 .
[4] A. Krieg,et al. Induction of Systemic TH1-Like Innate Immunity in Normal Volunteers Following Subcutaneous but Not Intravenous Administration of CPG 7909, a Synthetic B-Class CpG Oligodeoxynucleotide TLR9 Agonist , 2004, Journal of immunotherapy.
[5] F. Marincola,et al. Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma , 2009, Clinical Cancer Research.
[6] Emili Montserrat,et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. , 2006, Blood.
[7] T. Giese,et al. B-Cell Lymphomas Differ in their Responsiveness to CpG Oligodeoxynucleotides , 2005, Clinical Cancer Research.
[8] A. Bossler,et al. Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma , 2006, Journal of immunotherapy.
[9] A. Hart,et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Leonard,et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Oh,et al. Detailed kinetics of immune responses to a new cell culture-derived smallpox vaccine in vaccinia-naïve adults. , 2007, Vaccine.
[12] B. Comin-Anduix,et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Ankit Garg,et al. LesionViewer: A Tool for Tracking Cancer Lesions Over Time , 2007, AMIA.
[14] M. Goldstein,et al. Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. , 2009, Blood.
[15] J. Dutz,et al. Topical CpG enhances the response of murine malignant melanoma to dacarbazine. , 2008, The Journal of investigative dermatology.
[16] D. Czerwinski,et al. Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees. , 2009, Blood.
[17] T. Lister,et al. The clinical course of follicular lymphoma. , 2005, Best practice & research. Clinical haematology.
[18] Lin Chen,et al. Successful combination of local CpG‐ODN and radiotherapy in malignant glioma , 2005, International journal of cancer.
[19] R. Houot,et al. Idiotype vaccination for lymphoma: moving towards optimisation , 2009, Leukemia & lymphoma.
[20] B. LaFleur,et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Peschel,et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. , 2000, Blood.
[22] S. Akira,et al. Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself1 , 2007, The Journal of Immunology.
[23] R. Levy,et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. , 1992, The New England journal of medicine.
[24] Yuping Deng,et al. Age-Related Impaired Type 1 T Cell Responses to Influenza: Reduced Activation Ex Vivo, Decreased Expansion in CTL Culture In Vitro, and Blunted Response to Influenza Vaccination In Vivo in the Elderly1 , 2004, The Journal of Immunology.
[25] A. Mantovani,et al. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. , 2003, Blood.
[26] A. Órfão,et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. , 2006, Journal of the National Cancer Institute.
[27] A. Anichini,et al. Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. , 2009, Blood.
[28] Hua Liang,et al. Immune responses to vaccinia and influenza elicited during primary versus recent or distant secondary smallpox vaccination of adults. , 2006, Vaccine.
[29] J. Winter,et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] P. Schellhammer,et al. Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer , 2009, Cancer.
[31] W. Sterry,et al. Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma , 2008, Journal of immunotherapy.
[32] L. Zitvogel,et al. Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.
[33] Craig W. Reynolds,et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma , 2005, Nature Medicine.
[34] J. Winter,et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. Czerwinski,et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. , 2002, Blood.
[36] J. Leonard,et al. Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma , 2007, Clinical Cancer Research.
[37] P. Fournier,et al. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008 , 2009, Expert review of vaccines.
[38] T. Griffith,et al. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. , 2007, Cancer research.
[39] Stefano A Pileri,et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma , 2008, Haematologica.
[40] R. Negrin,et al. Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T‐regulatory cells , 2009, International journal of cancer.
[41] S. Ansell,et al. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. , 2005, Blood.